KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Lenvatinib Plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety From the Randomized Phase III Study 309/KEYNOTE-775.J Clin OncolPMID 37058687PMC104147272023-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial.JAMA DermatolPMID 37074705PMC101163862023-Jun-010.98未发现恶性肿瘤人群证据。待处理
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations.J Clin OncolPMID 37235976无 PMCID2023-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.N Engl J MedPMID 37256976PMC113350382023-Jun-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial.ThoraxPMID 35793833PMC103140342023-Jun0.98未发现恶性肿瘤人群证据。待处理
An analysis of feasibility of robotic colectomy: post hoc analysis of a phase III randomised controlled trial.J Robot SurgPMID 36525149无 PMCID2023-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials.J RheumatolPMID 36725056无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Traditional Vietnamese medicine Kovir capsule for non-severe COVID-19 patients: A phase III double-blind randomized controlled trial.Phytother ResPMID 36751127无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.Diabetes Obes MetabPMID 36782093无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Accurate tumor segmentation and treatment outcome prediction with DeepTOP.Radiother OncolPMID 36813177无 PMCID2023-Jun0.95The study uses data from a phase III RCT to develop and validate a deep learning tool for tumor segmentation and prediction of pathological complete response. It does not report time-to-event efficacy endpoints (OS, PFS, DFS, etc.) or Kaplan-Meier/HR results. Therefore, it is not eligible for the Kaplan-Meier digitization cohort.待处理
Randomized Placebo-Controlled Phase 3 Trial of Vibrating Capsule for Chronic Constipation.GastroenterologyPMID 36822371无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Cost-effectiveness of pembrolizumab in first-line for microsatellite-instability-high or mismatch-repair-deficient metastatic colorectal cancerF.J Oncol Pharm PractPMID 36823960无 PMCID2023-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Vincristine and dexamethasone pulses in addition to maintenance therapy among pediatric acute lymphoblastic leukemia (GD-ALL-2008): An open-label, multicentre, randomized, phase III clinical trial.Am J HematolPMID 36877527无 PMCID2023-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial.Eur UrolPMID 36894488无 PMCID2023-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy.Breast Cancer Res TreatPMID 36947277PMC101754502023-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Detailed Sub-study Analysis of the SECRAB Trial: Quality of Life, Cosmesis and Chemotherapy Dose Intensity.Clin Oncol (R Coll Radiol)PMID 37012180PMC101861162023-Jun0.95The record describes a sub-study analysis from the SECRAB trial focusing on quality of life, cosmesis, and chemotherapy dose intensity. It does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). The main trial efficacy (local recurrence) is mentioned in the abstract but is not the focus of this specific report, which is a secondary analysis of non-efficacy outcomes.待处理
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical Outcomes.Clin Pharmacol TherPMID 37017631无 PMCID2023-Jun0.90The study is a Phase III randomized trial of molnupiravir for COVID-19, not for human malignant neoplasm. It does not have a primary/key secondary time-to-event efficacy endpoint like OS or PFS; outcomes are based on logistic regression of hospitalization (binary).待处理
Rituximab biosimilar for the treatment of diffuse large B-cell lymphoma: a phase 3 randomized study in India.Cancer Chemother PharmacolPMID 37093266PMC101246902023-Jun0.85The study is an original Phase III randomized controlled trial of a drug-containing intervention (biosimilar rituximab) for human oncology (diffuse large B-cell lymphoma). However, the primary efficacy endpoint is objective response rate (ORR), which is not a time-to-event endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR). Therefore, it does not meet the criterion for a primary/key secondary time-to-event efficacy endpoint.待处理
Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn's disease: Results up to Week 104 of the STARDUST trial.United European Gastroenterol JPMID 37139642PMC102569882023-Jun0.98未发现恶性肿瘤人群证据。待处理
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial.Lancet Diabetes EndocrinolPMID 37148899无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.Lancet HIVPMID 37167996PMC102803942023-Jun0.98未发现恶性肿瘤人群证据。待处理
Effect of HPV self-collection kits on cervical cancer screening uptake among under-screened women from low-income US backgrounds (MBMT-3): a phase 3, open-label, randomised controlled trial.Lancet Public HealthPMID 37182529PMC102834672023-Jun0.85The record describes a phase 3 randomized trial in the oncology domain (cervical cancer screening) and is an original primary result report. However, the intervention consists of mailed HPV self-collection kits and scheduling assistance, which are non-drug interventions. Furthermore, the primary efficacy endpoint is cervical cancer screening uptake (a binary proportion), not a time-to-event endpoint such as OS, PFS, DFS, etc. Therefore, it fails the required criteria for drug intervention and time-to-event endpoint.待处理
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet OncolPMID 37182538无 PMCID2023-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.Lancet NeurolPMID 37210098无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.Lancet NeurolPMID 37210099无 PMCID2023-Jun0.90The record describes a Phase 3 randomized controlled trial of valbenazine for Huntington's disease chorea, which is not a malignant neoplasm. The primary endpoint is a change in a clinical rating scale (UHDRS TMC score), not a time-to-event efficacy endpoint such as overall survival or progression-free survival. Therefore, it does not meet the oncology or time-to-event criteria required for inclusion.待处理
Ivabradine for controlling heart rate in permanent atrial fibrillation: A translational clinical trial.Heart RhythmPMID 37245897无 PMCID2023-Jun0.98未发现恶性肿瘤人群证据。待处理
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial.Lancet OncolPMID 37269841PMC106419142023-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.Nat MedPMID 37291210PMC102875582023-Jun0.98未发现恶性肿瘤人群证据。待处理
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.Nat CancerPMID 37322367无 PMCID2023-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial.BMJ Open Diabetes Res CarePMID 37328272PMC102770512023-Jun0.98未发现恶性肿瘤人群证据。待处理
Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial.J Immunother CancerPMID 37399357PMC103146812023-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy of Gemigliptin Add-on to Dapagliflozin and Metformin in Type 2 Diabetes Patients: A Randomized, Double-Blind, Placebo-Controlled Study (SOLUTION).Endocrinol Metab (Seoul)PMID 37408283PMC103231602023-Jun0.98未发现恶性肿瘤人群证据。待处理
ELISA F29 -A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment.PLoS Negl Trop DisPMID 37352322PMC103250402023-Jun0.98未发现恶性肿瘤人群证据。待处理
N-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study.TrialsPMID 37248494PMC102262212023-May-290.98未发现恶性肿瘤人群证据。待处理
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial.LancetPMID 37086745无 PMCID2023-May-270.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.LancetPMID 37116524无 PMCID2023-May-270.98未发现恶性肿瘤人群证据。待处理
Hydrocortisone in Severe Community-Acquired Pneumonia.N Engl J MedPMID 36942789无 PMCID2023-May-250.98未发现恶性肿瘤人群证据。待处理
Meningococcal ACWYX Conjugate Vaccine in 2-to-29-Year-Olds in Mali and Gambia.N Engl J MedPMID 37224196PMC106274752023-May-250.98未发现恶性肿瘤人群证据。待处理
Upadacitinib Induction and Maintenance Therapy for Crohn's Disease.N Engl J MedPMID 37224198无 PMCID2023-May-250.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2-55 Years) in Japan: a Phase III Randomized Study.Jpn J Infect DisPMID 36724939无 PMCID2023-May-240.98未发现恶性肿瘤人群证据。待处理
Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial.Br J DermatolPMID 36967713无 PMCID2023-May-240.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials.Br J DermatolPMID 36994947无 PMCID2023-May-240.98未发现恶性肿瘤人群证据。待处理
INR and vitamin K-dependent factor levels after vitamin K antagonist reversal with 4F-PCC or plasma.Blood AdvPMID 36574241PMC101969912023-May-230.98未发现恶性肿瘤人群证据。待处理
NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial.VaccinePMID 37127523PMC101486682023-May-220.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.Chin Med J (Engl)PMID 37010251PMC102787592023-May-200.45The trial is a randomized Phase III oncology study with a drug intervention, but its primary efficacy endpoint is the percentage of patients achieving a pharmacodynamic endpoint (testosterone suppression ≤50 ng/dL) and its cumulative probability over a fixed time period (day 29 to 85). This is not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier curve or hazard ratio for such an endpoint is described.待处理
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.LancetPMID 37068504无 PMCID2023-May-201.00命中用户提供的消化道肿瘤阳性参考集。待处理
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy.J Clin OncolPMID 37196429无 PMCID2023-May-200.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg®) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial.Medicine (Baltimore)PMID 37335745PMC101944482023-May-190.80This is a Phase III randomized trial in human oncology patients with a drug intervention (pegteograstim). However, the primary endpoint is the duration of grade 4 neutropenia, which is a safety/toxicity measure, not a time-to-event efficacy endpoint such as OS, PFS, DFS, or TTP. The study does not report Kaplan-Meier curves or hazard ratios for a survival or tumor progression outcome. Therefore, it does not meet the key criterion of having a primary or key secondary time-to-event efficacy endpoint.待处理
Psychometric evaluation of the Symptoms of Infection with Coronavirus-19 (SIC): results from a cross-sectional study and a phase 3 clinical trial.J Patient Rep OutcomesPMID 37195456PMC101897062023-May-170.98未发现恶性肿瘤人群证据。待处理
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1).VaccinePMID 37105892无 PMCID2023-May-160.98未发现恶性肿瘤人群证据。待处理